Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
暂无分享,去创建一个
Martin C. Müller | R. Larson | M. Baccarani | G. Martinelli | D. Niederwieser | R. Silver | R. Conti | F. Mahon | W. Padula | R. Hehlmann | S. Dusetzina | C. Schiffer | F. Guilhot | J. Apperley | B. Simonsson | J. Mayer | J. Guilhot | S. Saussele | E. Eigendorff
[1] R. Larson,et al. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU , 2015, Annals of Hematology.
[2] M. D. de Lemos,et al. Clinical efficacy of generic imatinib , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[3] M. Baccarani,et al. Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056) , 2014 .
[4] J. Apperley,et al. Chronic myeloid leukemia-transplantation in the tyrosine kinase era. , 2014, Hematology/oncology clinics of North America.
[5] S. Pearson,et al. The ethics of 'fail first': guidelines and practical scenarios for step therapy coverage policies. , 2014, Health affairs.
[6] H. Kantarjian,et al. High cancer drug prices in the United States: reasons and proposed solutions. , 2014, Journal of oncology practice.
[7] T. Brümmendorf,et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. , 2014, Blood.
[8] E. Berndt,et al. Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001-2007 , 2014 .
[9] R. Larson,et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. , 2014, Blood.
[10] J. Cayuela,et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Allen,et al. Determining the cost of obesity and its common comorbidities from a commercial claims database , 2014, Clinical obesity.
[12] Aaron N. Winn,et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S. Goldberg,et al. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia , 2014, Journal of medical economics.
[14] M. Baccarani,et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). , 2014, Blood.
[15] F. Mahon,et al. Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy? , 2013, Clinical Cancer Research.
[16] Francisco Cervantes,et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.
[17] C. Cleeland,et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. , 2013, Blood.
[18] J. Melo,et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. , 2013, Blood.
[19] Francisco Cervantes,et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. , 2013, Blood.
[20] R. Larson,et al. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance , 2013, Leukemia.
[21] M. Weinstein,et al. Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States , 2013, Annals of Internal Medicine.
[22] W. Cullen,et al. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study , 2013, BMC Pharmacology and Toxicology.
[23] F. Mahon. Is going for cure in chronic myeloid leukemia possible and justifiable? , 2012, Hematology. American Society of Hematology. Education Program.
[24] N. Majhail,et al. Costs and cost-effectiveness of hematopoietic cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] H. Grabowski,et al. Longer Patents for Increased Generic Competition in the US , 2012, PharmacoEconomics.
[26] B. Motheral. Pharmaceutical Step-Therapy Interventions: A Critical Review of the Literature , 2011, Journal of managed care pharmacy : JMCP.
[27] M. Baccarani,et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. , 2011, Blood.
[28] K. Rezvani,et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. , 2010, Blood.
[29] Martin C. Müller,et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). , 2010, Blood.
[30] Philippe Rousselot,et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.
[31] Ricardo Pasquini,et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.
[32] D. Marin,et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] M. Gordon. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .
[34] A. Levy,et al. A multinational study of health state preference values associated with chronic myelogenous leukemia. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[35] J. Radich,et al. International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib , 2009 .
[36] M. Duh,et al. Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries , 2009, Current medical research and opinion.
[37] P. Martiat,et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. , 2009, Blood.
[38] K. Rezvani,et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. , 2008, Blood.
[39] R M Stone,et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib , 2008, Leukemia.
[40] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[41] Michael R. Ward,et al. Generic Drug Industry Dynamics , 2002, Review of Economics and Statistics.
[42] S. Wiggins,et al. Price Competition in Pharmaceuticals: The Case of Anti-infectives , 2004 .
[43] Susan Branford,et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.
[44] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[45] M. Gold. Cost-effectiveness in health and medicine , 2016 .
[46] Henry G. Grabowski,et al. Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act , 1992, The Journal of Law and Economics.